The Technical Analyst
Finch Therapeutics Group, [FNCH]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Finch Therapeutics Group, Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.73% $2.40
America/New_York / 23 apr 2024 @ 10:22
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.85 mill |
| EPS: | -46.59 |
| P/E: | -0.0500 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 1.606 mill |
| Avg Daily Volume: | 0.0317 mill |
| RATING 2024-04-22 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0500 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0500 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.12 - 2.71 ( +/- 12.24%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-28 | Smisek Jeffery A | Sell | 1 600 | Common Stock |
| 2024-03-28 | Smisek Jeffery A | Sell | 6 642 | Common Stock |
| 2023-11-22 | Smisek Jeffery A | Sell | 1 470 | Common Stock |
| 2023-06-09 | Blischak Matthew P. | Buy | 962 899 | Stock Option (right to buy) |
| 2023-06-08 | Blischak Matthew P. | Buy | 962 899 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 97.84 |
| Last 84 transactions |
| Buy: 22 938 760 | Sell: 28 923 806 |
Forecast:
12:01 - $2.48
Live Trading Signals (every 1 min)
Forecast
1: 10:31 - $2.41
Forecast 2: 11:21 - $2.53
Forecast 3: 12:01 - $2.48
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.40 (5.73% ) |
| Volume | 0.0575 mill |
| Avg. Vol. | 0.0317 mill |
| % of Avg. Vol | 181.28 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FNCH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
FNCH
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Latest Press Releases
2022-05-09 08:22:00 - Press Release
Finch Therapeutics To Host Corporate Update Conference Call And Webcast On May 16, 2022
Somerville, mass., may 09, 2022 (globe newswire) -- finch therapeutics group, inc. (“finch” or “finch therapeutics”) (nasdaq: fnch), a clinical-stage microbiome therapeutics company leveraging its human-first discovery ® platform to develop a novel class of orally administered biological drugs, today announced it will host a conference call and live webcast on monday, may 16, 2022 at 8:00am et to discuss updates to its development programs and other business highlights.
2021-10-12 07:00:00 - Press Release
Finch Therapeutics To Present At The Jefferies Virtual Next Generation Ibd Therapeutics Summit
Somerville, mass., oct. 12, 2021 (globe newswire) -- finch therapeutics group, inc. (“finch” or “finch therapeutics”) (nasdaq: fnch), a clinical-stage microbiome therapeutics company leveraging its human-first discovery® platform to develop a novel class of orally administered biological drugs, today announced that mark smith, phd, chief executive officer, will present at the jefferies virtual next generation ibd therapeutics summit on tuesday, october 19, 2021.
2021-10-05 07:00:00 - Press Release
Finch Therapeutics Appoints Samuel Allen Hamood To Its Board Of Directors
Somerville, mass., oct. 05, 2021 (globe newswire) -- finch therapeutics group, inc. (“finch” or “finch therapeutics”) (nasdaq: fnch), a clinical-stage microbiome therapeutics company leveraging its human-first discovery® platform to develop a novel class of orally administered biological drugs, today announced that samuel allen (al) hamood has joined finch's board of directors. mr. hamood is an accomplished executive with over 30 years of experience in finance, business development, corporate strategy, and m&a across several global industry sectors.
2021-09-07 07:00:00 - Press Release
Finch Therapeutics To Present At The H.c. Wainwright 23rd Annual Global Investment Conference
Somerville, mass., sept. 07, 2021 (globe newswire) -- finch therapeutics group, inc. (“finch” or “finch therapeutics”) (nasdaq: fnch), a clinical-stage microbiome therapeutics company leveraging its human-first discovery® platform to develop a novel class of orally administered biological drugs, today announced that mark smith, phd, chief executive officer, will present a company overview at the h.c. wainwright 23rd annual global investment conference being held september 13-15, 2021. the on-demand presentation will be available on monday, september 13, 2021 at 7:00 am et.
2021-08-10 07:05:00 - Press Release
Finch Therapeutics Reports Second Quarter 2021 Financial Results And Provides Business Update
Somerville, mass., aug. 10, 2021 (globe newswire) -- finch therapeutics group, inc. (“finch” or “finch therapeutics”) (nasdaq: fnch), a clinical-stage microbiome therapeutics company leveraging its human-first discovery® platform to develop a novel class of orally administered biological drugs, today reported financial results for the second quarter ended june 30, 2021 and provided a business update.
Latest News
2023-04-19 10:32:41 - PennyStocks
4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650%
Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-11-10 09:47:41 - Zacks Investment Research
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-09-05 13:33:08 - Zacks Investment Research
Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why
Finch Therapeutics Group, Inc. (FNCH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-05-09 08:22:00 - GlobeNewsWire
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced it will host a conference call and live webcast on Monday, May 16, 2022 at 8:00am ET to discuss updates to its development programs and other business highlights.
2022-04-29 12:10:42 - The Motley Fool
Why Finch Therapeutics Stock Is Skyrocketing Today
2022-04-29 12:10:15 - InvestorPlace
Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?
Finch Therapeutics (FNCH) stock is rising higher on Friday following news that the FDA has released its clinical hold on CP101. The post Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?
2022-04-29 09:32:40 - PennyStocks
Best Penny Stocks to Buy Today? 3 to Watch on April 29th
What you need to know about buying penny stocks on April 29th The post Best Penny Stocks to Buy Today? 3 to Watch on April 29th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-11-10 07:15:22 - Benzinga
Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study
Finch Therapeutics Group Inc (NASDAQ: FNCH) announced positive topline results from PRISM-EXT, an open-label extension of the PRISM3 Phase 2 trial evaluating CP101 to prevent recurrent C. difficile infection (CDI).
2021-10-12 07:00:00 - GlobeNewsWire
Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
SOMERVILLE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Tuesday, October 19, 2021.
2021-10-05 07:00:00 - GlobeNewsWire
Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors
SOMERVILLE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Samuel Allen (Al) Hamood has joined Finch's Board of Directors. Mr. Hamood is an accomplished executive with over 30 years of experience in finance, business development, corporate strategy, and M&A across several global industry sectors.